Zacks Industry Outlook Highlights: St. Jude Medical, Baxter, Becton Dickinson, Boston Scientific and Haemonetics.

For Immediate Release

Chicago, IL – June 11, 2009 – Zacks.com releases the latest Industry Outlook. Today’s interview is with senior analyst Christopher Titus, who talks about the Medical Devices Industry, including St. Jude Medical (STJ - Analyst Report), Baxter (BAX - Analyst Report) Becton Dickinson (BDX - Analyst Report), Boston Scientific (BSX - Analyst Report) and Haemonetics (HAE - Analyst Report).

A synopsis of today’s Industry Outlook is presented below. The full article can be read at http://at.zacks.com/?id=2678.

The medical products industry is very diverse, and some boats sit much higher in low tide than others. Even during recent economic turbulence, many of these names will continue performing well on a financial basis.

Areas within our coverage that should perform well include cardiovascular devices and surgical equipment, blood related products, and associated consumables. The names currently on our BUY list that we believe provide safe vehicles over the coming 12 months include St. Jude Medical (STJ - Analyst Report), Baxter (BAX - Analyst Report) Becton Dickinson (BDX - Analyst Report), Boston Scientific (BSX - Analyst Report) and Haemonetics (HAE - Analyst Report).

We are changing our opinion on medication dispensing, delivery and software to something more positive. Since the Obama Administration passed a health care stimulus package to incent hospitals and practices to modernize their health record keeping, we believe there are many smaller names that will benefit.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting: http://at.zacks.com/?id=2679.

About Zacks 

The performance of the Zacks Rank portfolios shown above for annual and year-to-date periods are the linked monthly total returns (price changes + dividends) of equal weighted hypothetical portfolios, consisting of those stocks with the indicated Zacks Rank, assuming monthly rebalancing and zero transaction costs. These are not the returns of actual portfolios. The hypothetical portfolios were created at the beginning of each month from Jan 1988 forward based on the values of the Zacks Rank available to Zacks' clients before the beginning of each month.

The portfolios created monthly from 1988 through September 2006 exclude ADRS and are comprised of stocks that have the indicated Zacks Rank and were covered by at least two analysts at the time of the stocks inclusion in the portfolio. Starting in October 2006 and going forward, the portfolios are comprised of all stocks with the indicated Zacks Rank and do not exclude ADRs, which is more reflective of the list of stocks that customers will find on the Zacks web sites. 2007 returns are for the period of Jan 1 – Jun 30, 2007. These performance numbers have been audited from 1995 through 2003 by Autschuler Melovan, a division of American Express Financial.